EP1877840A2 - Appareils ophtalmiques et procedes correspondants - Google Patents

Appareils ophtalmiques et procedes correspondants

Info

Publication number
EP1877840A2
EP1877840A2 EP06752318A EP06752318A EP1877840A2 EP 1877840 A2 EP1877840 A2 EP 1877840A2 EP 06752318 A EP06752318 A EP 06752318A EP 06752318 A EP06752318 A EP 06752318A EP 1877840 A2 EP1877840 A2 EP 1877840A2
Authority
EP
European Patent Office
Prior art keywords
lens
concentration
additive
methacrylate
blue light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06752318A
Other languages
German (de)
English (en)
Other versions
EP1877840A4 (fr
Inventor
Khalid Mentak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Medical Technologies Inc
Original Assignee
Key Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/350,396 external-priority patent/US7842367B2/en
Priority claimed from US11/388,212 external-priority patent/US7857848B2/en
Application filed by Key Medical Technologies Inc filed Critical Key Medical Technologies Inc
Publication of EP1877840A2 publication Critical patent/EP1877840A2/fr
Publication of EP1877840A4 publication Critical patent/EP1877840A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00—Producing optical elements, e.g. lenses or prisms
    • B29D11/02—Artificial eyes from organic plastic material
    • B29D11/023—Implants for natural eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2/1613—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus
    • A61F2/1659—Intraocular lenses having special lens configurations, e.g. multipart lenses; having particular optical properties, e.g. pseudo-accommodative lenses, lenses having aberration corrections, diffractive lenses, lenses for variably absorbing electromagnetic radiation, lenses having variable focus having variable absorption coefficient for electromagnetic radiation, e.g. photochromic lenses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00—Producing optical elements, e.g. lenses or prisms
    • B29D11/00634—Production of filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A61F2/16—Intraocular lenses
    • A61F2002/1696—Having structure for blocking or reducing amount of light transmitted, e.g. glare reduction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0053—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in optical properties

Definitions

  • This invention relates to ophthalmic devices or apparatuses, particularly intraocular lenses (IOLS), with improved contrast sensitivity and protection from UV and blue light.
  • This invention is particularly applicable to acrylic foldable IOLs and contact lenses. Novel methods of making ophthalmic devices also are disclosed.
  • blue light has a wavelength in the range of about 400-500 nm. If the blue light hazard is a real threat to vision, then the UV/visible transmission characteristics of ophthalmic lenses, and intraocular lenses (IOLs) in particular, should be modified to provide adequate protection from blue light hazards encountered in the environment. In the ambient environment solar radiation is the primary hazard to vision. The sun freely emits UV, visible and IR radiation much of which is absorbed by the atmosphere.
  • the solar radiation that is transmitted through the atmosphere and reaches the earth's surface consists of UV-B radiation (230-300 nm), near UV or UV-A radiation (300-400 nm), visible light (400-700 nm) and near IR radiation (700-1400 nm).
  • UV-B radiation is, however, absorbed by the cornea and does not reach the retina.
  • UV-A, and the blue portion of the visible spectrum can be absorbed by the crystalline lens of the eye depending upon the person's age.
  • the human crystalline lens changes its UV and visible transmission characteristics as it ages. In infancy the human lens will freely transmit near UV and visible light above 300 nm, but with further aging the action of UV radiation from the environment causes the production of yellow pigments, fluorogens, within the lens. By approximately the age of 54 the lens will not transmit light below 400 nm and the transmission of light between 400 and 500 nm is greatly diminished. As the lens ages it continuously develops a yellow color, increasing its capacity to filter out near UV and blue light.
  • the present invention relates, e.g., to the use of blue light blocking chromophores
  • BLBC blue light blocking IOL
  • IOL blue light filtering efficiency The disadvantages associated with existing blue light blocking IOLs are reduced or eliminated by optimizing the interaction of IOL blue light filtering efficiency with pupil size under various light conditions. In intense light conditions (i.e. sunlight, bright artificial light) the pupil is constricted to approximately 3 mm to allow less retinal light exposure. This is known as miosis.
  • the relatively higher chromophore concentration at the center of the lens protects the retina from damage. In dim light conditions, the pupil dilates to approximately 7 mm (or more) to allow more light to reach the retina
  • This invention permits optimization of the concentration of e.g., BLBC, by creation of a lens-center to lens-edge concentration decline or gradient commensurate with, or selected for, a patient's normal UV, blue light, etc., exposure.
  • concentration e.g., BLBC
  • lens-center to lens-edge concentration decline or gradient commensurate with, or selected for, a patient's normal UV, blue light, etc., exposure.
  • Additive is not to be narrowly construed so as
  • MADISONV722657 1 to avoid the fundamental nature of this invention.
  • the disclosure of the 11/388,212 application relating to creation and definition of an infinite refractive index gradient at page 15 through 17 is specifically incorporated by reference herein.
  • Other such additives where a concentrated gradient, preferably an infinite concentration gradient, will be suggested to one skilled in this and, in view of this invention.
  • the method of manufacture of the present invention involves the step of creating a central member or core e.g., by polymerization, having a higher concentration of e.g. BLBC, and then polymerizing around the core material a polymer sleeve or tube containing a lesser amount of chromophore, including none.
  • a central member or core e.g., by polymerization, having a higher concentration of e.g. BLBC
  • the second polymerization step at least some of the chromophore tends to migrate from the higher concentration core to the lesser concentration sleeve or perimeter material creating a uniform gradient.
  • an ophthalmic device e.g., an IOL
  • an IOL is created by creating the core material as described above and inserting the core material having a higher concentration chromophore into a lesser-chromophore-containing outer sleeve or rod which has been drilled, machined, laser-modified or otherwise modified, to create a central orifice or hole into which the colored central core is inserted.
  • the structure is completed by bonding the core material to the outer sleeve using such techniques as ultrasonic welding, monomer bonding, or solvent bonding.
  • the structure, thus created, when used to manufacture a lens has a more abrupt colored-colorless interface or boundary which is useful for some applications.
  • the method is not limited to deployment of a chromophore into what will become the lens of e.g. an IOL.
  • Any polymer additive, process enhancer, etc., for which a concentration gradient could provide an advantageous characteristic to the resulting ophthalmic device could be dispersed in a polymer material or property in accordance with this invention. Further, for some applications the concentration gradient or
  • the gradient could have a higher concentration of e.g. a chromophore or other polymer-modifying molecule, additive or comonomer at the edge of e.g. the IOL, with a lesser concentration toward the center of the IOL lens.
  • care must be taken so that the additive, whatever its purpose, does not leach from the lens structure.
  • leach of an additive from a gradient may be intended. All of the above variations are within the contemplation of the present invention.
  • FIGURE illustrating an intraocular lens of the present invention which is also produced in accordance with the methods of the present invention.
  • Suitable lens-forming monomers for use in the present invention include carbazole and/or naphthyl moiety, carbazole, naphthalene, or a naphthyl group such as vinyl carbazole, vinyl naphthalene, lauryl methacrylate, stearyl methacrylate, methyl methacrylate, 2-hydroxy ethyl acrylate, 2-hydroxyethyl methacrylate, 3-hydroxypropyl acrylate, 3-hydroxypropyl methacrylate, n- vinyl pyrolidone, styrene, eugenol (4-hydroxyvinylbenzene), and .alpha.-methylstyrene.
  • carbazole and/or naphthyl moiety such as vinyl carbazole, vinyl naphthalene, lauryl methacrylate, stearyl methacrylate, methyl methacrylate, 2-hydroxy ethyl acrylate, 2-hydroxyethyl methacrylate, 3-hydroxyprop
  • suitable monomers include, but are not limited to: 2-ethylphenoxy methacrylate, 2-ethylphenoxy acrylate, 2-ethylthiophenyl methacrylate, 2-ethylthiophenylacrylate, 2-ethylaminophenyl methacrylate, phenyl methacrylate, benzyl methacrylate, 2-phenylethyl methacrylate, 3-phenylpropyl methacrylate, 4-phenylbutyl methacrylate, 4-methylphenyl methacrylate, 4-methylbenzyl methacrylate, 2-2-methylphenylethyl methacrylate, 2-3-methylphenylethyl methacrylate,
  • MADISONV722657.1 2-(3-chlorophenyl)ethyl methacrylate, 2-(4-chloro-phenyl)ethyl methacrylate, 2-(4-bromophenyl)ethyl methacrylate, 2-(3-phenylphenyl)ethyl methacrylate, 2-(4-phenylphenyl)ethyl methacrylate), 2-(4-benzylphenyl)ethyl methacrylate, and the like, including the corresponding methacrylates and acrylates.
  • N- vinyl pyrolidone, styrene, eugenol and .alpha.-methyl styrene may also be suitable for high-refractive index foldable lens applications.
  • a preferred lens-forming monomer mixture is the mixture of vinyl carbazole, lauryl methacrylate, and hydroxyethyl acrylate.
  • the copolymerizable cross-linking agent used in the lens-materials of this invention may be any terminally ethylenically unsaturated compound having more than one unsaturated group.
  • Suitable cross-linking agents include, for example: ethylene glycol dimethacrylate, diethylene glycol dimethacrylate, allyl methacrylate, 1,3 -propanediol dimethacrylate, allyl methacrylate, 1,6-hexanediol dimethacrylate, 1,4-butanediol dimethacrylate, and the like.
  • a preferred cross-linking agent is ethylene glycol dimethacrylate.
  • Suitable crosslinkers also include polymeric crosslinkers, such as, polyethylene glycol 1000 diacrylate, polyethylene glycol 1000 dimethacrylate, polyethylene glycol 600 dimethacrylate, polybutanediol 2000 dimethacrylate, polypropylene glycol 1000 diacrylate, polypropylene glycol 1000 dimethacrylate, polytetramethylene glycol 2000 dimethacrylate, and polytetramethylene glycol 2000 diacrylate.
  • polymeric crosslinkers such as, polyethylene glycol 1000 diacrylate, polyethylene glycol 1000 dimethacrylate, polyethylene glycol 600 dimethacrylate, polybutanediol 2000 dimethacrylate, polypropylene glycol 1000 diacrylate, polypropylene glycol 1000 dimethacrylate, polytetramethylene glycol 2000 dimethacrylate, and polytetramethylene glycol 2000 diacrylate.
  • An ultra-violet absorbing material optionally can be included in the polymeric lenses of this invention in order that the lenses may have an ultraviolet absorbance approximately equivalent to that of the natural lens of the eye.
  • the optional ultraviolet absorbing material can be any compound which absorbs ultraviolet light, i.e., light having a wavelength generally shorter than about 400 nm, but does not absorb any substantial amount of visible light.
  • the ultraviolet absorbing compound generally is added to and dispersed into the monomer mixture prior to polymerization and is entrapped in the
  • Suitable ultraviolet absorbing compounds include vinyl anthracene, substituted benzophenones, such as 2-hydroxybenzophenone, and 2-(2-hydroxyphenyl)benzo-triazoles. It is preferred to use an ultraviolet absorbing compound which is copolymerizable with the monomers and is thereby covalently bound to the polymer matrix. In this way possible leaching of the ultraviolet absorbing compound out of the lens and into the interior of the eye is minimized.
  • Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S. Pat. No.
  • BLBCs Blue Light Blocking Chromophores
  • BLBC material can be any compound which absorbs violet/blue light, i.e., light having a wavelength between about 380 nm and about 570 nm and which can be adequately bound, e.g., by polymerization, absorption, adsorption, formation of covalent/ionic linkages, etc., to the base polymer.
  • Yellow and orange dyes, polymerizeable yellow and orange dyes, chromene, and any combination thereof are well known BLBC compounds which find uses herein.
  • a list of preferred orange chromophores is set forth at paragraph 8 of the previously incorporated-by-reference S.N. 11/350,396 application, that list being specifically incorporated herein. Many such BLBCs will be readily suggested to one skilled in the art in view of this invention.
  • the preferred BLBC is a combination of vinyl anthracene and disperse orange 3 methacrylamide.
  • Method I 1. The first step involves the production of the core material at the center of the
  • MADISONY722657.1 approximately 6 inches in length and 3mm in diameter is produced by polymerizing a base polymer containing 0.005% to 10% of BLBC in a Teflon mold. The polymer rod is removed from the mold cured and annealed for further processing.
  • the second step involves placing the rod produced in step 1 in a center of a cylindrical mold measuring 6 inches in length and 8 mm in diameter.
  • a solution of the base polymer with no BLBC is polymerized around the 3 mm rod to create a final polymer rod measuring 6 inches in length and 8 mm in diameter and having a maximum concentration of BLBC at the center of the rod.
  • the polymer rod is machined into 17 mm x 2 mm disks and IOLs were cut from the samples. This method creates IOLs with a gradient blue light blocking due to the diffusion of the monomer into the 3 mm rod during the second polymerization.
  • the first step of this method is the same as the first step of Method I.
  • the second step involves producing a base polymer rod containing no BLBC measuring approximately 6 inches in length and 8mm in diameter by polymerizing the base polymer in a Teflon mold. The rod is removed from the mold and a 3 mm hole is drilled in the center of the rod. The 3 mm rod prepared in step 1 is placed inside the hole drilled previously and the two materials bonded together using methods known in the art such as ultrasonic welding, monomer bonding, or solvent bonding.
  • %T per cent Transmission VC: vinyl carbazole VN:2-vinyl naphthalene EHA: 2-ethylhexylacrylate LM: Lauryl methacrylate HEMA; Hyroxyethylmethacrylate HEA : Hy dr oxyethylacr yl ate EGDM: ethylene glycol dimethacrylate VA: vinyl anthracene
  • MEB 2-(2'-Methacryloxy-5' methylphenyl)benzotriazole
  • DYA Disperse Yellow 7 Acrylate
  • DYM Disperse Yellow 7 methacrylate
  • DOM Disperse Orange 3 Methacrylamide
  • STEP 1 The comonomers listed above were mixed in a glass flask using a magnetic stir bar for at least 30 minutes followed by sonication, as discussed below, for the times indicated, and then stirring again for another 30 minutes.
  • the combination of sonication and hydrophilic/hydrophobic repulsion forces allows the formation of nanoclusters.
  • the size of the nanoclusters is theoretically controlled by the amount of energy provided during these steps.
  • Sonication for about 30 minutes at a power setting of 100% on a Branson 5510 provides optically clear materials with adequate optical and physical properties.
  • ABIN was added at a concentration of 0.2%.
  • the comonomer mixture with BLBC was vacuum degassed and placed in a Teflon tubular mold. The mold was placed in water bath at 70°C for 12 hours than cured at 100°C for 12 hours. A polymer rod measuring 3 mm in diameter and 6 inches in length was removed from the mold, cured and annealed for further processing.
  • STEP 2 The rod produced in step 1 was placed in a center of a cylindrical mold measuring 6 inches in length and 8 mm in diameter. A solution of the base polymer used in step 1, with no BLBC, and with 0.2% ABIN was poured around the 3 mm rod produced in step 1 and cured similarly to step 1. A final polymer rod measuring 6 inches in length and 8 mm in diameter and having a maximum concentration of BLBC at the center of the rod was produced The polymer rod was machined into 17 mm x 2 mm disks and IOLs were cut from the samples. The refractive index was measured using a CLR 12-70 refractometer from Index Instrument.
  • the optical properties of the IOLs were measured by UV/VIS spectroscopy using a DU-50 spectrophotometer from Beckman Instruments. To asses the efficiency of UV light and blue light blocking at various locations from the center of the lens, which represents eye exposure to different light conditions due to pupil size, light transmittance at key wavelengths was measured at three distances from the center of the IOL: 0 mm (center of the lens), 3.5 mm (just outside light exposure area when the light intensity is at maximum), and at 5.5 mm at the periphery of the lens when the pupil is fully dilated.
  • the IOL 10 of the FIGURE has a lens optic or lens body 10 with attached haptics 12.
  • Lens body 10 has an edge
  • the IOL shown in the FIGURE has an overall diameter of approximately
  • a region of concentrated chromophore 14 approximately 3mm in diameter.
  • the 3mm concentrated chromophore then is shown to merge into a gradient zone of chromophore at 16 produced as described above. If a more abrupt chromophoric interface or zone is desired as also as described above, that region or interface would be shown by the dotted circle 18 in the center of the lens optic 10.
  • a lens optic 10 a part or portion of an ophthalmic device (i.e., IOL 12) that can be produced in a practice of this invention.
  • IOL 12 an ophthalmic device

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Manufacturing & Machinery (AREA)
  • Mechanical Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

L'invention concerne des dispositifs ophtalmiques, en particulier des lentilles intraoculaires (IOL) qui présentent une plus grande sensibilité aux contrastes, et qui inhibent mieux les U.V. ambiants et la lumière ou assurent une meilleure protection contre les U.V. ambiants et la lumière bleue, en présence d'un gradient décroissant d'un chromophore bloquant la lumière bleue (BLBC), du centre de la lentille vers le bord de la lentille. Utilisé dans une IOL, le gradient décroissant BLBC améliore la vue du patient, notamment dans des conditions de lumière tamisée ou de faible luminosité.
EP06752318A 2005-05-05 2006-05-05 Appareils ophtalmiques et procedes correspondants Withdrawn EP1877840A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67791705P 2005-05-05 2005-05-05
US11/350,396 US7842367B2 (en) 2005-05-05 2006-02-08 Ultra violet, violet, and blue light filtering polymers for ophthalmic applications
US11/388,212 US7857848B2 (en) 2005-05-05 2006-03-23 Infinite refractive index gradient (IRIG) polymers for ocular implant and contact lens applications
PCT/US2006/017441 WO2006121876A2 (fr) 2005-05-05 2006-05-05 Appareils ophtalmiques et procedes correspondants

Publications (2)

Publication Number Publication Date
EP1877840A2 true EP1877840A2 (fr) 2008-01-16
EP1877840A4 EP1877840A4 (fr) 2010-05-19

Family

ID=37397142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06752318A Withdrawn EP1877840A4 (fr) 2005-05-05 2006-05-05 Appareils ophtalmiques et procedes correspondants

Country Status (3)

Country Link
EP (1) EP1877840A4 (fr)
JP (1) JP2008541798A (fr)
WO (1) WO2006121876A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8882267B2 (en) 2006-03-20 2014-11-11 High Performance Optics, Inc. High energy visible light filter systems with yellowness index values
US20120075577A1 (en) 2006-03-20 2012-03-29 Ishak Andrew W High performance selective light wavelength filtering providing improved contrast sensitivity
ES2397865T3 (es) 2006-10-13 2013-03-11 Novartis Ag Lentes intraoculares con límite único de azul-violeta y características de transmisión de luz azul
JP5273748B2 (ja) 2007-04-30 2013-08-28 アルコン，インコーポレイテッド 眼用レンズ材料用ｕｖ吸収剤
TWI453199B (zh) 2008-11-04 2014-09-21 Alcon Inc 用於眼用鏡片材料之紫外光／可見光吸收劑
DE102008063742A1 (de) * 2008-12-18 2010-07-01 *Acri.Tec Gmbh Farbstoff, ophthalmologische Zusammensetzung und ophthalmologische Linse
US9144491B2 (en) * 2011-06-02 2015-09-29 University Of Rochester Method for modifying the refractive index of an optical material
DE102013015386B4 (de) * 2012-10-22 2019-03-14 Hartwig Becker Intraokularlinse

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3428895A1 (de) * 1984-08-04 1986-02-13 Dr. K. Schmidt-Apparatebau, 5205 St Augustin Intraokularlinse
EP0331457A2 (fr) * 1988-03-04 1989-09-06 Alcon Surgical, Inc., Méthode de préparation de lentilles à bord coloré
US4961746A (en) * 1985-08-23 1990-10-09 American Cyanamid Company Intraocular lens with colored legs and method of making
WO2005066694A2 (fr) * 2003-12-29 2005-07-21 Advanced Medical Optics, Inc. Lentilles intra-oculaires a zone de transmission selective de la lumiere visible

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470932A (en) * 1993-10-18 1995-11-28 Alcon Laboratories, Inc. Polymerizable yellow dyes and their use in opthalmic lenses
US5846457A (en) * 1994-10-28 1998-12-08 Hoffman; William C. Light filtering contact lens method
JPH119616A (ja) * 1997-06-19 1999-01-19 Kazuo Ichikawa 眼用レンズ
US6645246B1 (en) * 1999-09-17 2003-11-11 Advanced Medical Optics, Inc. Intraocular lens with surrounded lens zone
US6391049B1 (en) * 1999-10-06 2002-05-21 Board Of Regents The University Of Texas System Solid biodegradable device for use in tissue repair
WO2003011351A2 (fr) * 2001-08-02 2003-02-13 Johnson & Johnson Vision Care, Inc. Lentilles antimicrobiennes et procedes d'utilisation
JP2004121434A (ja) * 2002-09-30 2004-04-22 Nidek Co Ltd 眼内レンズの着色方法及び該方法にて得られる着色眼内レンズ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3428895A1 (de) * 1984-08-04 1986-02-13 Dr. K. Schmidt-Apparatebau, 5205 St Augustin Intraokularlinse
US4961746A (en) * 1985-08-23 1990-10-09 American Cyanamid Company Intraocular lens with colored legs and method of making
EP0331457A2 (fr) * 1988-03-04 1989-09-06 Alcon Surgical, Inc., Méthode de préparation de lentilles à bord coloré
WO2005066694A2 (fr) * 2003-12-29 2005-07-21 Advanced Medical Optics, Inc. Lentilles intra-oculaires a zone de transmission selective de la lumiere visible

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2006121876A2 *

Also Published As

Publication number Publication date
WO2006121876A2 (fr) 2006-11-16
WO2006121876A3 (fr) 2009-04-23
EP1877840A4 (fr) 2010-05-19
JP2008541798A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
US7857848B2 (en) Infinite refractive index gradient (IRIG) polymers for ocular implant and contact lens applications
US7842367B2 (en) Ultra violet, violet, and blue light filtering polymers for ophthalmic applications
EP2983618B1 (fr) Dispositif de lentille phakique pourvu d'ouvertures et de zones annulaires concentriques
US6353069B1 (en) High refractive index ophthalmic device materials
ES2585632T3 (es) Dispositivo oftálmico reflectivo-difractivo y composiciones útiles para fabricar el mismo
WO2006121876A2 (fr) Appareils ophtalmiques et procedes correspondants
US20150359625A1 (en) Toric-diffractive lens
EP1079870B1 (fr) Lentille intraoculaire bicomposite et son procede de preparation
US20080137030A1 (en) Optical devices with reduced chromatic aberration
AU741716B2 (en) High refractive index ophthalmic device materials
JP2023052498A (ja) 眼適用のためのポリマーおよび方法
US7771470B2 (en) Ophthalmic apparatuses and methods
EP3188690B1 (fr) Lentille intraoculaire personnalisée pour un astigmatisme ou une presbytie et un astigmatisme combinés
MXPA00001526A (en) Ophthalmic lens polymers

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17P Request for examination filed

Effective date: 20080701

DAX Request for extension of the european patent (deleted)
R17D Deferred search report published (corrected)

Effective date: 20090423

RIC1 Information provided on ipc code assigned before grant

Ipc: C08J 7/00 20060101ALI20090430BHEP

Ipc: G02B 1/04 20060101AFI20090430BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100419

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/16 20060101ALI20100413BHEP

Ipc: A61L 27/50 20060101ALI20100413BHEP

Ipc: C08J 7/00 20060101ALI20100413BHEP

Ipc: G02B 1/04 20060101AFI20090430BHEP

17Q First examination report despatched

Effective date: 20110629

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20160208